# EPANOVA in Crohn's Disease, Study 1

> **NCT00613197** · PHASE3 · COMPLETED · sponsor: **Tillotts Pharma AG** · enrollment: 384 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Epanova

## Key facts

- **NCT ID:** NCT00613197
- **Lead sponsor:** Tillotts Pharma AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** 2006-08
- **Final completion:** 2006-08
- **Target enrollment:** 384 (ACTUAL)
- **Last updated:** 2013-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00613197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00613197, "EPANOVA in Crohn's Disease, Study 1". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00613197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*